IntelGenX
IntelGenx (now Nualtis) is a Canadian pharmaceutical technology company that develops and manufactures proprietary oral thin film drug delivery platforms — VersaFilm® for human health and VetaFilm® for animal health — via B2B licensing, co-development, and contract GMP manufacturing partnerships with pharmaceutical companies globally.
- Company typePrivate
- Founded2002
- HeadquartersSaint Laurent, Canada
- Headcount11–50
- GTM typeB2B
- OfferingServices
What IntelGenX does
IntelGenx Technologies Corp., now operating as Nualtis, is a Canadian specialty pharmaceutical company headquartered in Saint Laurent, Quebec, founded in 2002. The company develops and manufactures oral thin film (OTF) drug delivery technologies, organized around two proprietary platforms: VersaFilm® for human health applications and VetaFilm® for animal health. The core technology enables drug delivery through oral mucosal absorption, offering enhanced bioavailability, reduced first-pass metabolism, precise dose control, and water-free administration — addressing limitations of conventional tablets and capsules, particularly for pediatric, geriatric, and veterinary patients. IntelGenx holds over 30 US patents covering formulations and manufacturing processes.
The company operates a B2B partnership model, monetizing its technology through out-licensing of existing products, co-development agreements with pharmaceutical partners (from concept to commercialization), and contract GMP manufacturing services. Revenue is generated through licensing royalties, milestone payments, co-development fees, and manufacturing service contracts, with all arrangements conducted on a quote-based, non-publicly disclosed basis. Customer segments include human health pharmaceutical companies, animal health/veterinary pharmaceutical companies, and licensing partners. The company provides vertically integrated capabilities spanning R&D, analytical method development, regulatory submissions to FDA/EMA/global agencies, cGMP manufacturing from pilot to commercial scale, and QA release with serialization support.
Named commercial partners include US Exeltis & Xiromed, Gensco Pharma, and atai Life Sciences AG, the last of which is both a strategic shareholder (with board representation) and a pipeline collaborator. IntelGenx has sustained a multi-year funding relationship with AtaiBeckley/atai since 2021, with the most recent round in December 2023 totaling US$750,000 via convertible notes and warrants, and an option for additional investment through August 2026. The company trades on OTCQX under the symbol IGXT and is led by CEO Dr. Michael Raven, supported by CSO Nadine Paiement, VP Quality Nina Pourhassan, and BD Lead & General Counsel Tommy Kenny.
IntelGenX firmographics
Firmographics- Name
- IntelGenX
- Legal name
- IntelGenx Technologies Corp.
- Website
- https://intelgenx.com
- Company type
- Private
- Founded year
- 2002
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- IntelGenx (now Nualtis) is a Canadian pharmaceutical technology company that develops and manufactures proprietary oral thin film drug delivery platforms — VersaFilm® for human health and VetaFilm® for animal health — via B2B licensing, co-development, and contract GMP manufacturing partnerships with pharmaceutical companies globally.
- Ownership category
- akta.pro rank
IntelGenX industry classification
Industry- Product category
- Pharmaceutical Drug Delivery
- NAICS
- Pharmaceutical Preparation Manufacturing (325412), Surgical and Medical Instrument Manufacturing (339112)
- SIC
- Pharmaceutical Preparations (2834), Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Ophthalmic & Otic Generics (HLAIABAF)
- akta.pro secondary industry
- Livestock & Production Animal Therapeutics (Rx) (HLAMAEAB)
Keywords
Where IntelGenX is headquartered
LocationHeadquarters
- HQ city
- Saint Laurent
- HQ country
- Canada
- HQ region
- North America
Markets served
IntelGenX business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations, Supply Chain, Infrastructure, Marketing or Sales
Revenue model
- Licensing and Co-development Partnerships: IntelGenx partners with pharmaceutical companies to co-develop and commercialize oral film products, generating revenue through licensing deals, co-development fees, and milestone payments. The company also offers its existing portfolio of products available for out-licensing.
- Contract Manufacturing Services: The company provides GMP manufacturing services to pharmaceutical partners, offering analytical, R&D, and manufacturing capabilities from pilot scale to commercial production. Revenue is generated through service contracts and manufacturing fees.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels5 records
IntelGenX product offering
Product offeringCore offering
IntelGenx (operating as Nualtis) develops and manufactures proprietary oral thin film drug delivery platforms for pharmaceutical and veterinary applications. The company operates two product platforms — VersaFilm® for human health and VetaFilm® for animal health — and provides end-to-end services including R&D, GMP-compliant contract manufacturing, and analytical and regulatory support to pharmaceutical partners through licensing, co-development, and out-licensing arrangements.
Product overview
Nualtis (formerly IntelGenx) offers a platform-based product architecture built around two proprietary oral film technology platforms: VersaFilm® for human health applications and VetaFilm® for animal health. The company operates as both a product developer and a service provider, offering pharmaceutical companies end-to-end support through research and development, GMP manufacturing, and analytical and regulatory services. The VersaFilm® platform delivers medications directly through oral mucosal lining for enhanced bioavailability and faster onset, while the VetaFilm® platform provides palatable, room-stable films for animal dosing. With over 30 US patents, the company focuses on novel drug delivery through innovative oral thin film technology for both human and veterinary applications.
Differentiator
Problem solved
Functional benefit
Brands
- VersaFilm®: Proprietary platform for human health oral film products enabling enhanced bioavailability, systemic absorption, and precision dosing through oral mucosal delivery.
- VetaFilm®
Products and services
- VersaFilm® Platform
Quantifiable outcome
- Faster onset of action and reduced dosage requirements compared to conventional tablets or capsules
- +1 more outcomes
Companies that use IntelGenX
Customer profileNamed customers2 records
Segments3 records
Ideal customer profiles2 records
IntelGenX technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature6 records
IntelGenX partnerships and signals
Strategic signalPartnerships
Two partnerships are on record, tiered core.
- US Exeltis & XiromedcoreUS Exeltis & Xiromed partners with Nualtis to leverage the thin-film platform for complex formulations, turning ideas into practical solutions and providing patients with high-quality, affordable treatment options. CEO Robert Spina has publicly endorsed the partnership.
- Gensco PharmacoreGensco Pharma partners with Nualtis to access world-class oral film delivery technology and manufacturing strength, aiming to bring more accessible treatments to patients. CEO Dr. Paul Zimmerman has publicly endorsed the partnership.
Scale indicators2 records
Recent moves6 records
Expansion highlights6 records
IntelGenX competitors and assessment
Company assessmentDirect peers
- Cure Pharmaceutical (CureRx): Cure Pharmaceutical develops oral thin film drug delivery technologies (CureFilm) and offers contract manufacturing of oral dissolvable films. It competes directly with Nualtis in offering licensing, co-development, and GMP manufacturing services centered on oral film platforms.
- ZIM Laboratories: ZIM Laboratories is an India-based specialty pharmaceutical company developing oral thin film (Thinoral) and other innovative drug delivery platforms. It offers formulation, licensing, and manufacturing services comparable to Nualtis' VersaFilm® offering and targets similar global pharma partners.
- Tapemark: Tapemark is a contract developer and manufacturer specializing in transdermal patches and oral thin films, serving pharmaceutical and consumer health companies. It overlaps directly with Nualtis in GMP oral film manufacturing and co-development services.
- BioDelivery Sciences International: BioDelivery Sciences International (now part of Collegium Pharmaceutical) developed oral transmucosal film products such as Bunavail using its BEMA® delivery technology. It is a direct historical peer in oral thin film drug delivery, particularly in pain and addiction therapeutics.
- Aquestive Therapeutics: Aquestive Therapeutics is a direct competitor in oral soluble film drug delivery, with proprietary PharmFilm® technology and a portfolio that includes treatments for allergy, migraine, and seizure rescue. Both companies commercialize oral thin film platforms to global pharma partners and compete for similar co-development mandates.
- LTS Lohmann Therapie-Systeme: LTS Lohmann Therapie-Systeme is a leading global manufacturer of oral thin film and transdermal drug delivery systems, serving as both a CDMO and licensor to pharmaceutical companies. It directly competes with Nualtis in formulation expertise, patent depth, and contract manufacturing services for oral film products.
- Adhex Pharma: Adhex Pharma develops and manufactures oral thin films and transdermal patches, serving pharmaceutical companies globally. It is a direct peer to Nualtis in formulation, licensing, and GMP manufacturing of oral film-based pharmaceutical products.
Broad incumbents
- Catalent: Catalent is a large global CDMO offering oral film, softgel, and other drug delivery capabilities as part of a broad pharmaceutical services portfolio. While not specialized in oral films alone, it competes with Nualtis for partnership and manufacturing mandates from mid-sized and large pharma companies.
Market position
Weaknesses5 records
Competitive moat4 records
Key risks5 records
Key highlights7 records
Customer concentration
IntelGenX social profiles
Digital presenceIntelGenX financial estimates
Financial estimateRevenue estimate
Valuation estimate
IntelGenX leadership team
Management profileNumber of profiles
Profiles5 records
IntelGenX funding detail
Funding detailFunding overview
Funding rounds20 records
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
IntelGenX M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about IntelGenX
What does IntelGenX do?
IntelGenx (operating as Nualtis) develops and manufactures proprietary oral thin film drug delivery platforms for pharmaceutical and veterinary applications. The company operates two product platforms — VersaFilm® for human health and VetaFilm® for animal health — and provides end-to-end services including R&D, GMP-compliant contract manufacturing, and analytical and regulatory support to pharmaceutical partners through licensing, co-development, and out-licensing arrangements.
Is IntelGenX a public or private company?
IntelGenX is a private company. It is classified as venture growth investor backed and is currently operating.
When was IntelGenX founded?
IntelGenX was founded in 2002. It employs 11 to 50 people.
Where is IntelGenX based?
IntelGenX is headquartered in Saint Laurent, Canada, in the North America region.
How does IntelGenX make money?
Two revenue lines are on record. Licensing and Co-development Partnerships are the primary driver. The others are contract Manufacturing Services.
Who are IntelGenX's main competitors?
Direct peers on record are Cure Pharmaceutical (CureRx), ZIM Laboratories, Tapemark, BioDelivery Sciences International, Aquestive Therapeutics, LTS Lohmann Therapie-Systeme and Adhex Pharma. Catalent is listed as a broad incumbent.
Does IntelGenX have an API?
No public API is recorded for IntelGenX.
What industry is IntelGenX in?
IntelGenX's product category is Pharmaceutical Drug Delivery. Its primary akta.pro industry code is HLAIABAF, Ophthalmic & Otic Generics, with a secondary code of HLAMAEAB, Livestock & Production Animal Therapeutics (Rx). Its NAICS code is 325412 and its SIC code is 2834.